IDEXX delivered a beat-and-raise quarter with accelerating top-line growth and margin expansion. The raised guidance signals confidence in sustained momentum from innovation (IDEXX Cancer Dx, inVue Dx) and improving clinical visit trends. Watch for continued execution on premium instrument placements and international expansion as key catalysts.
Price Chart
Executive Summary
IDEXX reported Q1 2026 revenue of $1.141B (+14% YoY) and GAAP EPS of $3.47 (+17% YoY), beating consensus estimates of $1.11B and $3.42. The company raised its full-year 2026 revenue guidance to $4.675B-$4.760B (up ~1% at midpoint) and EPS guidance to $14.45-$14.90, driven by strong CAG Diagnostics recurring revenue growth of 14% and operating margin expansion.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $1.141B, +14% YoY as reported and +11% organic, beating consensus of $1.11B
- GAAP EPS of $3.47, +17% YoY, beating consensus of $3.42
- CAG Diagnostics recurring revenue grew 14% as reported and 11% organic
- Raised FY2026 revenue guidance to $4.675B-$4.760B (from $4.632B-$4.720B), +$42M at midpoint
- Raised FY2026 EPS guidance to $14.45-$14.90 (from $14.29-$14.80), +$0.13 at midpoint
- Operating margin of 31.8%, up 10 bps as reported and 100 bps on a comparable basis
- Gross margin expanded 90 bps to 63.4%
- Operating cash flow of $266M, free cash flow of $234M
Financial Impact
Revenue beat consensus by ~$31M (2.8%), EPS beat consensus by $0.05 (1.5%)
Risk Factors
- Foreign exchange headwinds (~0.9% revenue impact, $0.27 EPS impact in guidance)
- Potential tariff impacts on supply chain and costs
- CEO transition from Jay Mazelsky to Mike Erickson introduces leadership uncertainty
- Loss on equity investment of $5M in Q1 could recur
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-055203 |
| Document: tm2613510d1_8k.htm | 0001104659-26-055203 |
| Document: 0001104659-26-055203-index-headers.html | 0001104659-26-055203 |
| Document: 0001104659-26-055203-index.html | 0001104659-26-055203 |
| Document: 0001104659-26-055203.txt | 0001104659-26-055203 |
| 8-K Data (Synthetic) | 0001104659-26-055203 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $588.09 $545.16 | ▼ −7.30% | ▼ −6.06% | $518.39 (−11.85%) |
May 5, 2026 21w ago | 8-K | $560.55 $550.82 | ▼ −1.74% | ▼ −6.69% | $518.39 (−7.52%) |
Mar 27, 2026 27w ago | DEFA14A | $556.91 $568.05 | ▲ +2.00% | ▼ −10.60% | $518.39 (−6.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access